SGLT2is and GLP-1 RAs Show Best Cardiovascular Results when Initiated Sooner
The case for why SGLT2is or GLP-1 receptor agonists should be initiated early in diabetes treatment, regardless of whether the
Uncategorized
The case for why SGLT2is or GLP-1 receptor agonists should be initiated early in diabetes treatment, regardless of whether the